| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6241144 | Respiratory Medicine | 2016 | 6 Pages |
Abstract
Adalimumab is an effective alternative for patients intolerant to infliximab. The switch to adalimumab achieved clinical improvement in 39% and stabilization in 33% of patients intolerant to infliximab. Further research is needed to develop guidelines on how to use adalimumab for sarcoidosis in terms of dosing regimen.
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
Heleen A. Crommelin, Leone M. van der Burg, Adriane D.M. Vorselaars, Marjolein Drent, Coline H.M. van Moorsel, Ger T. Rijkers, Vera H.M. Deneer, Jan C. Grutters,